African countries fast tracking efforts to end TB in the region
The new expanded list of countries with access to negotiated MGIT prices, the new ULTRA cartridge for GenXpert and new partnership to accelerate innovations between FIND and Stop TB Partnership were announced
Addis Ababa, Ethiopia – 24 March 2017 – World TB Day
2017 was commemorated in Addis Ababa today by a panel event
co-hosted by the Stop TB Partnership, FIND, BD (Becton,
Dickinson and Company) and Cepheid, and introduced by the first
director of the Africa Centres for Disease Control and
Prevention (Africa CDC), Dr John Nkengasong and Dr Lucica Ditiu,
the Executive Director of the Stop TB Partnership.
The panel took place following a meeting of the newly launched
Africa CDC held in collaboration with NEPAD and AIDS Watch
Africa. At that event, Her Excellency Amira Al Fadil, AU
Commissioner for Social Affairs, focused attention on the impact
of tuberculosis (TB) in Africa with her remarks: “Ending
TB in Africa is a responsibility on all our shoulders, as it is
a shame that TB still kills almost 700 000 people on our
continent every year. We are committed to ending this
disease.”
The panel, “How can achieving universal health care
accelerate efforts to end TB and meet the Sustainable
Development Goals?” provided a platform for speakers to
share country success stories in expanding universal health-care
and discuss the challenges faced by countries in reaching
missing TB cases.
In his introductory remarks, Dr Nkengasong noted that the
establishment of Africa CDC demonstrated the strong commitment
of African leaders to tackle public health threats such as TB.
“Ending TB, the world’s number one infectious
disease killer, requires functioning health systems, robust
national surveillance capacity and strong laboratory networks,
all among our strategic priorities. Ending TB will also require
partnerships between institutions and across sectors, whether
public, private, national or international.”
The event also provided a welcome platform to facilitate
accelerated action and share commitments to scaling up TB case
finding in the African region. In that context, several concrete
commitments were made to increase access to affordable TB
diagnosis.
Following joint negotiations conducted by BD, FIND, Stop TB
Partnership and UNDP, Dr Renuka Gadde, Vice President of Global
Health for BD, shared that earlier today, BD had signed an
agreement to improve access to BD technology used to diagnose TB
for 40 additional low- and middle-income countries, making a
total of 85 countries that are eligible for access pricing.
“Today we are pleased to add an additional 40 low- and
middle-income countries with high TB burden, as defined by
WHO,” said Dr Gadde.
Cepheid talked about their new, second-generation Xpert test for
TB. "The Xpert MTB/RIF Ultra will be introduced gradually in
2017 following the World Health Organization recommendation that
it can be used as an alternative to or a replacement for the
existing test for the diagnosis of TB and detection of
rifampicin resistance in all settings,” said Philippe
Jacon, President, Emerging Markets at Cepheid. WHO had earlier
today issued a report of their expert evaluation of the
Xpert® MTB/RIF Ultra, Cepheid’s new version of the
Xpert® MTB/RIF test, which concluded that the new Ultra test
showed better performance than Xpert MTB/RIF in detecting TB in
difficult-to-diagnose and vulnerable populations, such as
children and people living with HIV, and in those with
extra-pulmonary TB.[1]
As well, the Stop TB Partnership and FIND announced a strategic
partnership to support innovators of new tools for TB,
especially for diagnosis, to ensure that appropriate diagnostic
tests are reaching the market, as demanded and needed by those
affected by TB.
“On World TB Day, we so often just make statements. This
year, we have several concrete commitments to share with our
colleagues, partners and country programmes – more will
have access to MGIT with a better price, the Xpert Ultra
cartridge will help to increase case finding of people affected
by TB and we are forcefully going ahead together with FIND to
support innovators in the diagnostics space through our
Accelerator for Impact (a4i) initiative,” said Dr Lucica
Ditiu, Executive Director of the Stop TB Partnership. “And
our TB REACH and GDF teams are already pushing forward with new
tools.”
“It has been hugely encouraging to hear from African
leaders about the progress being made, the strategic directions
being mapped out to end TB in the region and the commitment to
laboratory strengthening across the continent,” said Dr
Catharina Boehme, CEO of FIND. “We must fill the
diagnostic gaps to increase TB case finding and halt ongoing
transmission. Today we have committed to working together to
advance this agenda.”
[1] WHO Meeting Report of a Technical Expert Consultation: Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Available at: http://apps.who.int/iris/handle/10665/254792
Source:
Stop TB Partnership